FDA (Drugs) recall action 70452

Attix Pharmaceuticals recalled 470 products on 2015-04-29

The FDA (Drugs) publishes a recall like this one as 470 separate product records. They share a firm, a date and a cause; this page is all of them in one place, so the scale of the action is visible rather than spread across 470 pages.

Products: 470
Announced: 2015-04-29
Critical: 0
Units: 2,350

Why these products were recalled

Penicillin Cross Contamination: All lots of all products repackaged and distributed between 01/05/12 and 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Penicillin Cross Contamination: All lots of all products repackaged between 01/05/12 through 02/12/15 are being recalled because they were repackaged in a facility with penicillin products without adequate separation which could introduce the potential for cross contamination with penicillin.

Stability Data Does Not Support Expiry: All lots of all products repackaged and distributed between 01/05/12 through 02/12/15 are being recalled because they were repackaged without data to support the printed expiry date.

The agency’s own wording, quoted from the enforcement report.

The unit total adds up the quantities the agency stated for each product. Where a product record gave no figure, or gave a weight rather than a count, it contributes nothing — so the real total is at least this, never less.

326–350 of 470

SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Hydroxocobalamin Acetate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Hydroxocobalamin Acetate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Hydroxocobalamin Acetate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Tolvaptan API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Tolvaptan active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Tolvaptan active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Diphenylcyclopropenone Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling diphenylcyclopropenone active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Diphenylcyclopropenone active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Vidarbine Monophosphate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Vidarbine Monophosphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Vidarbine Monophosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls 4-Aminopyridine Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling 4-Aminopyridine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
4-Aminopyridine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Bovine Insulin Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Bovine Insulin active pharmaceutical ingredient distributed between January 5, 2012, and February 12, 2015, due to potential penicillin cross-contamination.
Product
Bovine Insulin active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Ibuprofen Ingredient Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling ibuprofen active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Ibuprofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Methotrexate Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Methotrexate Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Methotrexate Sodium active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls 2-Deoxy-D-Glucose Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling 2-Deoxy-D-Glucose active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
2-Deoxy-D-Glucose active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, On
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Levothyroxine Sodium Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Levothyroxine Sodium active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Levothyroxine Sodium (T4) active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Lodenafil Carbonate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Lodenafil Carbonate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Lodenafil Carbonate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Mebendazole Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Mebendazole active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Mebendazole active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Paromomycin Sulphate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Paromomycin Sulphate active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Paromomycin Sulphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Mitotane API Recalled for Potential Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling Mitotane active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Mitotane active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Acetazolamide API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling Acetazolamide active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Acetazolamide active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Baclofen API Recalled for Potential Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling Baclofen active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Baclofen active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Histamine Diphosphate Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Histamine Diphosphate active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
Histamine Diphosphate active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Lisinopril Due to Penicillin Cross Contamination Risk
Attix Pharmaceuticals is recalling Lisinopril active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Lisinopril active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Famotidine API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling famotidine active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Famotidine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
D-Cycloserine API Recalled for Potential Penicillin Cross-Contamination
Attix Pharmaceuticals is recalling D-Cycloserine active pharmaceutical ingredient due to potential penicillin cross-contamination during repackaging.
Product
D-Cycloserine active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Avanafil API Recalled for Potential Penicillin Cross Contamination
Attix Pharmaceuticals is recalling all lots of Avanafil active pharmaceutical ingredient distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Avanafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Potassium Phosphate Monobasic Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling all lots of Potassium Phosphate Monobasic distributed between January 2012 and February 2015 due to potential penicillin cross-contamination.
Product
Potassium Phosphate Monobasic pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Tadalafil API Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Tadalafil active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Tadalafil active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
SevereFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Tiopronin Base Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Tiopronin Base active pharmaceutical ingredient due to potential penicillin cross-contamination from inadequate facility separation.
Product
Tiopronin Base active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states
HighFDA (Drugs)··2015-04-29
Attix Pharmaceuticals Recalls Dapiprazole HCl Due to Penicillin Cross-Contamination Risk
Attix Pharmaceuticals is recalling Dapiprazole HCl active pharmaceutical ingredient due to potential penicillin cross-contamination from repackaging in a shared facility.
Product
Dapiprazole HCl active pharmaceutical ingredient packaged in varying grams or kg in bags or drums, Attix Pharmaceuticals, 184 Front Street East, Unit 801, Toronto, Ontario M5A 4N3, Canada
Category
Distribution
0 states